# Bria-IMT

Source: https://onco.cc/drugs/bria-imt/  
OnCo record `bria-imt` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Bria-IMT is an off-the-shelf immunotherapy made from laboratory-grown cancer cells, from BriaCell Therapeutics. It is being tested with a checkpoint inhibitor in a phase 3 trial in metastatic breast cancer.

## Summary

Bria-IMT is the lead candidate of BriaCell Therapeutics, which describes it as a patented, off-the-shelf, cell-based targeted immunotherapy. It is being compared, with the checkpoint inhibitor retifanlimab, against treatment of the physician's choice in advanced metastatic breast cancer in the phase 3 trial NCT06072612 (BRIA-ABC), which plans 404 participants. BriaCell states that the FDA granted Bria-IMT Fast Track status.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-11-04
- Tags: pipeline
- Modality: Off-the-shelf cell-based immunotherapy
- Mechanism: Described by BriaCell Therapeutics as a patented, off-the-shelf, cell-based targeted immunotherapy, given with an immune checkpoint inhibitor. The ClinicalTrials.gov record of the phase 3 trial lists SV-BR-1-GM, cyclophosphamide and interferon infiltration of the inoculation site among the interventions of the Bria-IMT regimen.

## Sources

- BriaCell Therapeutics: https://briacell.com/
- ClinicalTrials.gov: NCT06072612: https://clinicaltrials.gov/study/NCT06072612

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- companies: [BriaCell Therapeutics](https://onco.cc/companies/briacell/)
- trials: [Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.](https://onco.cc/trials/nct06072612/)

---
JSON: https://onco.cc/api/v1/entities/bria-imt.json